Price History

Hover for the daily close. The dotted line marks the period open.

Compare HCWB with… →

HCWB Key Statistics

As of Sep 4, 2026

Trading

Open: $2.81
Previous Close: $2.87
Day's Range: 2.80–2.97
52-Week Range: 1.50–36.65
Volume: 35.60K
Beta: 2.38

Valuation

Market Cap: $5.40M
P/E Ratio: unprofitable
P/S ratio: 0.80
EPS (ttm): −16.62

Financials (FY)

Revenue (FY): $54.23K−97.89%
Net Income (FY): −$7.96M
Profit margin: −83.05%
Shares Outstanding: 1.84M
1-Year Return: −89.42%

Dividend and dates

Avg Volume: 138.96K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

HCWB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−63.17%−17.46%−36.03%−63.59%−94.56%−49.54%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−49.54%
2025	−94.56%
2024	−63.59%
2023	−36.03%
2022	−17.46%
2021 (partial year)	−63.17%

As of September 4, 2026.

HCWB Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$54.23K	−$7.96M	−14677.1%
2024	$2.57M	−$30.02M	−1169.7%
2023	$2.84M	−$24.99M	−879.5%
2022	$6.72M	−$14.90M	−221.7%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$54.23K	$10.85K	−$11.26M	−$7.96M	−14677.1%
2024	$2.57M	$959.40K	−$27.63M	−$30.02M	−1169.7%
2023	$2.84M	$560.36K	−$25.72M	−$24.99M	−879.5%
2022	$6.72M	$2.59M	−$15.08M	−$14.90M	−221.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HCWB Valuation vs Biotechnology Median

Median of 656 stocks

Metric	HCWB	Biotechnology median	vs median
P/S ratio	0.80	15.26	0.1x the median
Profit margin	−83.05%	0.00%	83.0 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

HCW Biologics Inc. (HCWB) carries a market capitalisation of $5.40M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 35.

The 52-week range on file runs from $1.50 to $36.65. The most recent close on file for HCWB is $2.94, dated September 4, 2026. That is +$0.07 (+2.44%) against the previous close. The latest close sits 96% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $54.23K. That is −97.89% against the prior fiscal year, when revenue was $2.57M. The same year closed with a net loss of $7.96M. The reported profit margin is −83.05%. That is 83 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −16.62.

Across the 4 fiscal years on file, revenue moves from $6.72M in 2022 to $54.23K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 0.8 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −89.42%. Across 5 years the annualized return works out at −68.34%. The reported beta is 2.38. Annualized volatility over the trailing 5 years is 237.48%.

Growth & Income

No dividend is on file for HCWB.

The strongest complete calendar year on file is 2022 at −17.46%; the weakest is 2025 at −94.56%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the price is −49.54% year to date.

Peer Comparison

HCW Biologics Inc. (HCWB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
HCW Biologics Inc.	HCWB	$5.40M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. HCW Biologics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About HCW Biologics Inc.

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Visit website →

HCW Biologics Inc. (HCWB) Stock Analysis